Expertise in
16
conditions

Dr. Matthew I. Milowsky

Oncology | Hematology
University Of North Carolina At Chapel Hill
101 Manning Dr, 
Chapel Hill, NC 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Expertise in
16
conditions
University Of North Carolina At Chapel Hill
101 Manning Dr, 
Chapel Hill, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Matthew Milowsky is an Oncologist and a Hematologist in Chapel Hill, North Carolina. Dr. Milowsky is highly rated in 16 conditions, according to our data. His top areas of expertise are Urothelial Cancer, Bladder Cancer, Muscle Invasive Bladder Cancer, Orchiectomy, and Tissue Biopsy. Dr. Milowsky is currently accepting new patients.

His clinical research consists of co-authoring 188 peer reviewed articles and participating in 22 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology
Licenses
Internal Medicine in NY
Hospital Affiliations
Unc Hospitals
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Essence Healthcare
  • INSURANCE PLAN
  • MEDICARE MAPD
FirstCarolinaCare
  • HMO
  • MEDICARE MAPD
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Trillium
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
101 Manning Dr, Chapel Hill, NC 27514

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

21 Clinical Trials

A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)
A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)
Enrollment Status: Recruiting
Publish Date: December 17, 2025
Intervention Type: Procedure, Biological, Drug
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 2
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
Enrollment Status: Active_not_recruiting
Publish Date: December 02, 2025
Intervention Type: Other, Biological, Procedure
Study Drug: Nivolumab
Study Phase: Phase 3
An Open Label, Multicenter, Single Arm Phase II Study to Evaluate the Activity and Tolerability of the Novel mTOR Inhibitor, MLN0128 (TAK-228), in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelial Tract Whose Tumors Harbor a TSC1 and/or a TSC2 Mutation
An Open Label, Multicenter, Single Arm Phase II Study to Evaluate the Activity and Tolerability of the Novel mTOR Inhibitor, MLN0128 (TAK-228), in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelial Tract Whose Tumors Harbor a TSC1 and/or a TSC2 Mutation
Enrollment Status: Active_not_recruiting
Publish Date: December 01, 2025
Intervention Type: Drug
Study Drug: Sapanisertib
Study Phase: Phase 2
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 3
Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Gemcitabine Hydrochloride, Pembrolizumab
Study Phase: Phase 2
Window of Opportunity Platform Study to Define Immunogenomic Changes With Pembrolizumab Alone and in Rational Combinations in Muscle-Invasive Bladder Cancer
Window of Opportunity Platform Study to Define Immunogenomic Changes With Pembrolizumab Alone and in Rational Combinations in Muscle-Invasive Bladder Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 15, 2025
Intervention Type: Procedure, Drug
Study Drugs: Pembrolizumab, Entinostat
Study Phase: Phase 2
A Phase 2, Randomized, Open-Label Study of Trilaciclib Administered With First-Line Platinum-Based Chemotherapy and Avelumab Maintenance Therapy in Patients With Untreated, Locally Advanced or Metastatic Urothelial Carcinoma (PRESERVE 3)
A Phase 2, Randomized, Open-Label Study of Trilaciclib Administered With First-Line Platinum-Based Chemotherapy and Avelumab Maintenance Therapy in Patients With Untreated, Locally Advanced or Metastatic Urothelial Carcinoma (PRESERVE 3)
Enrollment Status: Terminated
Publish Date: September 08, 2025
Intervention Type: Drug
Study Drugs: Trilaciclib, Gemcitabine, Cisplatin, Carboplatin, Avelumab
Study Phase: Phase 2
Randomized Phase II Trial of Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-Risk Germ Cell Tumors
Randomized Phase II Trial of Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-Risk Germ Cell Tumors
Enrollment Status: Active_not_recruiting
Publish Date: July 03, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Randomized Phase 2 Trial of Cisplatin/Gemcitabine With or Without M6620 (VX-970) in Metastatic Urothelial Carcinoma
A Randomized Phase 2 Trial of Cisplatin/Gemcitabine With or Without M6620 (VX-970) in Metastatic Urothelial Carcinoma
Enrollment Status: Completed
Publish Date: March 03, 2025
Intervention Type: Drug
Study Drugs: Berzosertib, Cisplatin, Gemcitabine Hydrochloride
Study Phase: Phase 2
Phase II Single Arm Study of Gemcitabine and Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Prior to Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer
Phase II Single Arm Study of Gemcitabine and Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Prior to Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 10, 2025
Intervention Type: Drug
Study Drugs: Pembrolizumab, Gemcitabine, Cisplatin
Study Phase: Phase 2
A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) As First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors
A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) As First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Drug, Procedure
Study Drugs: Paclitaxel, Ifosfamide, Cisplatin, Pegylated G-CSF, G-CSF, Carboplatin, Etoposide Phosphate
Study Phase: Phase 3
A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) With Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer
A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) With Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drugs: Gemcitabine, Cisplatin, Methotrexate, Vinblastine, Doxorubicin, Filgrastim
Study Phase: Phase 2
Phase 2 Trial of Tremelimumab in Patients With Metastatic Urothelial Cancer Previously Treated With PD-1/PD-L1 Blockade
Phase 2 Trial of Tremelimumab in Patients With Metastatic Urothelial Cancer Previously Treated With PD-1/PD-L1 Blockade
Enrollment Status: Completed
Publish Date: July 03, 2024
Intervention Type: Drug
Study Drug: Tremelimumab
Study Phase: Phase 2
Phase 2 Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations
Phase 2 Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations
Enrollment Status: Completed
Publish Date: November 22, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-blinded, Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer: Hoosier Cancer Research Network GU14-182
A Randomized, Double-blinded, Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer: Hoosier Cancer Research Network GU14-182
Enrollment Status: Completed
Publish Date: September 30, 2022
Intervention Type: Other, Drug
Study Phase: Phase 2
Quantification and Characterization of Circulating Tumor Cells in Solid Tumors
Quantification and Characterization of Circulating Tumor Cells in Solid Tumors
Enrollment Status: Completed
Publish Date: September 28, 2022
Intervention Type: Other
A Pilot Study of Early Intervention for Impairments Identified During Comprehensive Geriatric Assessment in Patients With Muscle-invasive Bladder Cancer
A Pilot Study of Early Intervention for Impairments Identified During Comprehensive Geriatric Assessment in Patients With Muscle-invasive Bladder Cancer
Enrollment Status: Terminated
Publish Date: October 18, 2021
Intervention Type: Other
Study Phase: Not Applicable
Feasibility Study of a Home-Based Exercise Intervention Program for Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Androgen Deprivation Therapy (ADT)
Feasibility Study of a Home-Based Exercise Intervention Program for Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Androgen Deprivation Therapy (ADT)
Enrollment Status: Completed
Publish Date: April 20, 2021
Intervention Type: Behavioral
Study Phase: Not Applicable
LCCC 1231: Observational Longitudinal Study of Pain in Men With Metastatic Castrate-Resistant Prostate Cancer
LCCC 1231: Observational Longitudinal Study of Pain in Men With Metastatic Castrate-Resistant Prostate Cancer
Enrollment Status: Completed
Publish Date: March 30, 2020
Intervention Type: Behavioral
Phase II Trial of Palbociclib (PD-0332991) in Patients With Metastatic Urothelial Cancer (UC) After Failure of First-Line Chemotherapy
Phase II Trial of Palbociclib (PD-0332991) in Patients With Metastatic Urothelial Cancer (UC) After Failure of First-Line Chemotherapy
Enrollment Status: Terminated
Publish Date: November 16, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 20 Less Clinical Trials

187 Total Publications

Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274.
Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: September 05, 2025
Similar Doctors
Expertise in
15
conditions
Dr. Sascha A. Tuchman
Hematology | Oncology | Transplant Surgery
Expertise in
15
conditions
Dr. Sascha A. Tuchman
Hematology | Oncology | Transplant Surgery

University Of North Carolina At Chapel Hill

101 Manning Dr, 
Chapel Hill, NC 
 (0.1 miles away)
984-974-1000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Sascha Tuchman is a Hematologist and an Oncologist in Chapel Hill, North Carolina. Dr. Tuchman is highly rated in 15 conditions, according to our data. His top areas of expertise are Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Monoclonal Gammopathy of Undetermined Significance (MGUS), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Tuchman is currently accepting new patients.

Expertise in
27
conditions
Dr. Anne Beaven
Hematology | Oncology
Expertise in
27
conditions
Dr. Anne Beaven
Hematology | Oncology

University Of North Carolina At Chapel Hill

101 Manning Dr, 
Chapel Hill, NC 
 (0.1 miles away)
984-974-1000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Anne Beaven is a Hematologist and an Oncologist in Chapel Hill, North Carolina. Dr. Beaven is highly rated in 27 conditions, according to our data. Her top areas of expertise are Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Aspiration, and Bone Marrow Transplant.

Expertise in
15
conditions
Dr. Frances Collichio
Hematology | Oncology
Expertise in
15
conditions
Dr. Frances Collichio
Hematology | Oncology

University Of North Carolina At Chapel Hill

101 Manning Dr, 
Chapel Hill, NC 
 (0.1 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Frances Collichio is a Hematologist and an Oncologist in Chapel Hill, North Carolina. Dr. Collichio is highly rated in 15 conditions, according to our data. Her top areas of expertise are Melanoma, Astrocytoma, Glioblastoma, and Oligodendroglioma.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Milowsky's expertise for a condition
ConditionClose
View All 10 Advanced Conditions
View All 12 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile